DUBLIN--(BUSINESS WIRE)--Jul 31, 2018--The "Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators" report has been added to ResearchAndMarkets.com's offering.

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators.

C ompetitor projects are listed in a tabular format providing information on:

Drug Codes Target / Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information

Reports Included

Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists

1b) PD-L1 Inhibitors

2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines

Report 2: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

1a) CTLA-4 Receptor Antagonists

1b) LAG-3 Antagonists

1c) TIM-3 Antagonists

1d) TIGIT Antagonists

1e) Other Inhibitors of Negative Immune Checkpoints

2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines

Report 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators

1) Corporate Immune Checkpoint Activator R&D Pipelines

Report 4: Tumor Microenvironment Modulation via IDO, TGF-, CXCR4, CSF-1R, CD47-SIRP, adenosine pathway & STING 2018

1a) IDO & TDO Inhibitors

1b) TGF-beta Inhibitors

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

1g) Adenosine Pathway Modulation

1h) STING Agonists

2) Corporate Tumor Microenvironment Modulator R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/p3sgnd/2018_report?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005639/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Oncology,Immunosuppressive Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/31/2018 10:28 AM/DISC: 07/31/2018 10:28 AM

http://www.businesswire.com/news/home/20180731005639/en